Search Results 1741-1750 of 18791 for Relapse

1. Urology Clinical Trials - Medical Professionals

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...

2. Clinical trials - Oncology (Medical)

   KTX-100 MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma. Rochester, Minn., Jacksonville, Fla ...

3. Multiple sclerosis fuels artist's work Video Audio ---NATS piano ---- May Ling Kopecky "When I'm playing music, and I feel

   "Her MRIs have been stable, and she's not had any new attacks or new relapses." Gait monitoring is a tool that's helping clinicians, like neurologist Dr ...

4. Publications - Paul J. Farnsworth, D.O. - Mayo Clinic

   ... relapse after allogeneic stem cell transplantation. Exp Hematol Oncol. 2012 Sep 17; 1 (1):29 Epub 2012 Sept 17. View PubMed. PST-20557589. Home; Publications ...

5. Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD - Mayo Clinic

   Specific for wAIHA: Relapsed from, did not respond to, or did not tolerate at least one prior wAIHA treatment regimen (such as prednisone, rituximab).

6. A Study to Evaluate Brigatinib Before Brain Irradiation - Mayo Clinic

   ... relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy. Participating Mayo Clinic locations. Study statuses change ...

7. A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant - Mayo Clinic

   Multiple myeloma which has relapsed following primary therapy or is not responsive to primary therapy. For this study, stable disease following ASCT will be ...

8. Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis - Mayo Clinic

   -Absence of clinical relapses for at least 24 months. -The participant must have an EDSS score at screening from 3.0 to 6.5 points, inclusive ...

9. Mayo Clinic physicians present research findings at 2016 ASTRO Annual Meeting

   ... relapse with at least one site of recurrence identified by CholPET. Researchers examined sites of recurrence with respect to radiation fields and patient ...

10. A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Participants with Mycobacterium Avium Complex (MAC) Pulmonary Disease - Mayo Clinic

    Has recent sputum or BAL culture evidence of recurrent or relapsed disease and 3. Has been off therapy for at least 3 months prior to consent 5. Has ...